Agenus to host investor webcast to review late-breaking botensilimab and balstilimab data presented at esmo world gi congress

Lexington, mass., june 21, 2022 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the company will host a hybrid webcast to discuss botensilimab/balstilimab combination data in microsatellite stable colorectal cancer (mss-crc) presented earlier that day in a late-breaking oral presentation at the esmo world congress on gastrointestinal cancer in barcelona, spain.
AGEN Ratings Summary
AGEN Quant Ranking